BAFF Receptor Antibody
| Code | Size | Price |
|---|
| PSI-3097-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-3097-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
BAFF Receptor Antibody: BAFFR, CD268, CVID4, BAFF-R, BROMIX, prolixin, BAFFR, BR3, Tumor necrosis factor receptor superfamily member 13C, B-cell-activating factor receptor
Application Note:
BAFF Receptor antibody can be used for detection of BAFF Rexeptor by Western blot at 5 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL.
Antibody validated: Western Blot in human, mouse, and rat samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human, mouse, and rat samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
BAFF Receptor Antibody: Members in the TNF superfamily regulate immune responses and induce apoptosis. A novel member in the TNF family was recently identified by several groups and designated BAFF, BLyS, TALL-1, THANK, and zTNF4. BAFF/BLyS was characterized as a B cell activator since it induced B cell proliferation and immunoglobulin secretion. Two receptors, TACI and BCMA, for BAFF were originally identified. A third receptor was identified recently and designated BAFF-R and BR3 for BLyS receptor 3. Unlike BCMA and TACI, which bind to BAFF and April, BAFF-R/BR3 is specific for BAFF and plays a predominant role in BAFF induced B cell development and survival. BAFF and its receptors are involved in B cell associated autoimmune diseases, and activate NF-κB and c-jun N-terminal kinase.
Background References:
- Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999;285:260-3
- Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189:1747-56
- Shu HB, Hu WH, Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 1999;65:680-3
- Mukhopadhyay A, Ni J, Zhai Y, Yu GL, Aggarwal BB. Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-κB, and c-Jun NH2-terminal kinase. J Biol Chem 1999 ;274:15978-81
Buffer:
BAFF Receptor Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
BAFF Receptor antibody was raised against a synthetic peptide corresponding to 15 amino acids near the carboxy terminus of human BAFF Receptor The peptide sequence is identical between human and mouse origin.
The immunogen is located within the last 50 amino acids of BAFF Receptor.
The immunogen is located within the last 50 amino acids of BAFF Receptor.
NCBI Gene ID #:
115650
NCBI Official Name:
tumor necrosis factor receptor superfamily, member 13C
NCBI Official Symbol:
TNFRSF13C
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
20 kDa
Protein Accession #:
AAK91826
Protein GI Number:
15208475
Purification:
BAFF Receptor Antibody is affinity chromatography purified via peptide column.
Research Area:
Chemokines & Cytokines
Swissprot #:
Q96RJ3
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | BAFF Receptor Peptide | PSI-3097P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|